Scientific Research and Essays

  • Abbreviation: Sci. Res. Essays
  • Language: English
  • ISSN: 1992-2248
  • DOI: 10.5897/SRE
  • Start Year: 2006
  • Published Articles: 2734

Review

Bacteriophages and phage products: Applications in medicine and biotechnological industries, and general concerns

Mulugeta Belay
  • Mulugeta Belay
  • Institute of Biotechnology, Addis Ababa University, Ethiopia.
  • Google Scholar
Tesfaye Sisay
  • Tesfaye Sisay
  • Institute of Biotechnology, Addis Ababa University, Ethiopia.
  • Google Scholar
Tesfaye Wolde
  • Tesfaye Wolde
  • College of Natural and Computational Science, Wolkite University, Anzire, Shewa, Ethiopia.
  • Google Scholar


  •  Received: 21 October 2017
  •  Accepted: 20 December 2017
  •  Published: 30 March 2018

References

Abdul-Hassan H, El-Tahan E, Massoud E, Gomaa R (1990). Bacteriophage therapy of pseudomonas burn wound sepsis. Ann. Medit. Burn Club 3:262-264.

 

Abedon S, Kuhl S, Blasdel B, Kutter E (2011). Phage treatment of human infections. Bacteriophage1:66-85.

 

Abedon ST (2009). Phage evolution and ecology. Adv. Appl. Microbiol.67:1-45.
Crossref

 

Abhilash M, Vidya A, Jagadevi T (2008). Bacteriophage therapy: a war against antibiotic resistant bacteria. Internet J. Altern. Med. 7:e17744

 

Acar J, Rostel B (2001). Antimicrobial resistance: an overview. Rev Sci. Technol. 20:797-810.
Crossref

 

Adhya S, Merril CR, Biswas B (2014). Therapeutic and prophylactic applications of bacteriophage components in modern medicine. Cold spring harb. Perspect. Med. 4:a012518.
Crossref

 

Aghebati-Maleki L, Bakhshinejad B, Baradaran B, Motallebnezhad M, Aghebati-Maleki A, Nickho H (2016). Phage display as a promising approach forvaccine development. J. Biomed. Sci. 23:66-84.
Crossref

 

Alemayehu D, Casey PG, McAuliffe O, Guinane CM, Martin JG, Shanahan F (2012). Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio3: e00029-12.

 

Asheshov IN, Wilson J, Topley WWC (1934). The effect of an anti-VI bacteriophage on typhoid infection in mice. Lancet 1:319-320.

 

Babalova EG, Katsitadze KT, Sakvarelidze LA, Imnaishvili N, Sharashidze TG, Badashvili VA (1968). Preventive value of dried dysentery bacteriophage. Zh. Mikrobiol. Epidemiol. Immunobiol. 45:143-145.

 

Bao HD, Zhang PY, Zhang H, Zhou Y, Zhang LL, Wang R (2015). Bio-control of Salmonella enteritidis in foods using bacteriophages. Viruses 7:4836-4853.
Crossref

 

Bigwood T, Hudson JA, Billington C, Carey-Smith GV, Heinemann JA (2008). Phage inactivation of foodborne pathogens on cooked and raw meat. Food Microbiol. 25:400-406.
Crossref

 

Biswas B, Adhya S, Washart P, Paul B, Trostel AN, Powell B (2002). Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin–resistant Enterococcus faecium. Infect. Immun. 70:204-210.
Crossref

 

Boratynski J, Syper D, Weber-Dabrowska B, Lusiak-Szelachowska M, Pozniak G, Gorski A (2004). Preparation of endotoxin-free bacteriophages. Cell Mol. Biol. Lett. 9:253-259.

 

Borysowski J, Weber-Dąbrowska B, Górski AJ (2006). Current status and perspectives of phage therapy. Adv. Clin. Exp. Med.15:575-580.

 

Bren L (2007). Bacteria-eating virus approved as food additive. FDA Consum. 41:20-22.

 

Broudy TB, Fischetti VA (2003). In vivo lysogenic conversion of Tox(-) Streptococcus pyogenes to Tox(+) with lysogenic streptococci or free phage. Infect. Immun. 71:3782-3786.
Crossref

 

Brussow H (2012). What is needed for phage therapy to become a reality in Western medicine? Virol. 434:138-142.
Crossref

 

Bueno E, García P, Martínez B, Rodríguez A (2012). Phage inactivation of S. aureus in fresh and hard-type cheeses. Int. J. Food Microbiol.158:23-27.
Crossref

 

Carlton RM (1999). Phage therapy: past history and future prospects. Arch. Immunol. Ther. Exp. (Warsz). 47:267-274.

 

Carvalho CM, Gannon BW, Halfhide DE, Santos SB, Hayes CM, Roe JM (2010). The in vivo efficacy of two administration routes of a phage cocktail to reduce numbers of Campylobacter coli and Campylobacter jejuni in chickens. BMC Microbiol. 10:232-242.
Crossref

 

Chan BK, Sistrom M, Wertz JE, Kortright KE, Narayan D, Turner PE (2016). Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci. Rep. 6:26717-26724.
Crossref

 

Cheng Q, Nelson D, Zhu S, Fischetti VA (2005). Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob. Agents Chemother. 49:111-117.
Crossref

 

Chhibber S, Kumari S (2012). Application of therapeutic phages in medicine. In: Bacteriophages, (Kurtböke, I., ed). InTech, Croatia. pp. 140-158.
Crossref

 

Chhibber S, Kaur S, Kumari S (2008). Therapeutic potential of bacteriophage in treating Klebsiella pneumoniae B5055-mediated lobar pneumonia in mice. J. Med. Microbiol. 57:1508-1513.
Crossref

 

Cislo M, Dabrowski M, Weber-Dabrowska B, Woyton A (1987). Bacteriophage treatment of suppurative skin infections. Arch. Immunol. Ther. Exp. (Warsz) 35:175-183.

 

Clark JR, March JB (2004a). Bacterial viruses as human vaccines? Expert Rev. Vaccines 3:463-476.
Crossref

 

Clark JR, March JB (2004b). Bacteriophage-mediated nucleic acid immunisation. FEMS Immunol. Med. Microbiol. 40:21-26.
Crossref

 

Clark JR, March JB (2006). Bacteriophages and biotechnology: Vaccines, gene therapy and antibacterials. Trends Biotechnol. 24: 212-218.
Crossref

 

Clokie MRJ, Kropinski AM (2009). Bacteriophages: Methods and Protocols, Volume 1: Isolation, Characterization, and Interactions. Humana Press, New York.

 

Colom J, Cano-Sarabia M, Otero J, Cortés P, Maspoch D, Llagostera M (2015). Liposome-encapsulated bacteriophages for enhanced oral phage therapy against Salmonella spp. Appl. Environ. Microbiol. 81:4841-4849.
Crossref

 

Corbitt AJ, Bennion N, Forsythe SJ (2000). Adenylate kinase amplification of ATP bioluminescence for hygiene monitoring in the food and beverage industry. Lett. Appl. Microbiol. 30:443-447.
Crossref

 

d'Herelle F (1926). The Bacteriophage and Its Behavior. Williams and Wilkins, Baltimore, Maryland.
Crossref

 

Davis BM, Waldor MK (2003). Filamentous phages linkedto virulence of Vibrio cholerae. Curr. Opin. Microbiol. 6: 35-42.
Crossref

 

de la Cruz VF, Lal AA, McCutchan TF (1988). Immunogenicity and epitope mapping of foreign sequences via genetically engineered filamentous phage. J. Biol. Chem. 263:4318-4322

 

Dickerson TJ, Kaufmann GF, Janda KD (2005). Bacteriophage-mediated protein delivery into the central nervous system and its application in immunopharmacotherapy. Expert Opin. Biol. Ther. 5:773-781.
Crossref

 

Ding Y, Niu YD, Stanford K, Holley R, McAllister T, Narvaez-Bravo C (2016). Biocontrol of verotoxigenic Escherichia coli in vitro and on Romaine lettuce using lytic phages at different temperatures. Poster presented at: Annual Meeting of IAFP 2016; Jul 31-Aug 3, St. Louis, Missouri. Abstract retrieved at: https://iafp.confex.com/iafp/2016/webprogram/Paper12023.html

 

Edgar R, Friedman N, Molshanski-Mor S, Qimron U (2012). Reversing bacterial resistance to antibiotics by phage mediated delivery of dominant sensitive genes. Appl. Environ. Microbiol.78:744-751.
Crossref

 

El-Shibiny A (2016). Bio-control of E. coli and Salmonella in foods using bacteriophage to improve food safety. World J. Dairy Food Sci.11:150-155.

 

El-Shibiny A, Scott A, Timms A, Metawea Y, Connerton P, Connerton I (2009). Application of a group II Campylobacter bacteriophage to reduce strains of Campylobacter jejuni and Campylobacter coli colonizing broiler chickens. J. Food Protect. 724):733-740.

 

Fan H, Tong Y (2012). Potential duel-use of bacteriophage related technologies in bioterrorism and biodefense. J. Bioterr. Biodef. 3:121-124.
Crossref

 

Fang J, Wang G, Yang Q, Song J, Wang Y, Wang L (2005). The potential of phage display virions expressing malignant tumor specific antigen MAGE-A1 epitope in murine model. Vaccine 23:4860-4866.
Crossref

 

Favrin SJ, Jassim SA, Griffiths MW (2003). Application of a novel immunomagnetic separationbacteriophage assay for the detection of Salmonella enteritidis and Escherichia coli O157:H7 in food. Int. J. Food Microbiol. 85:63-71.
Crossref

 

Fischetti VA (2011). Exploiting what phage have evolved to control gram-positive pathogens. Bacteriophage 1:188-194.
Crossref

 

Fish R, Kutter E, Wheat G, Blasdel B, Kutateladze M, Kuhl S (2016). Bacteriophage treatment of intransigent diabetic toe ulcers: a case series. J. Wound Care 7:S27-33.
Crossref

 

Funatsu T, Taniyama T, Tajima T, Tadakuma H, Namiki H (2002). Rapid and sensitive detection method of a bacterium by using a GFP reporter phage. Microbiol. Immunol. 46:365-369.
Crossref

 

Galarce NE, Bravo JL, Robeson JP, Borie CF (2014). Bacteriophage cocktail reduces Salmonella enterica serovars enteritidis counts in raw and smoked salmon tissues. Rev. Argent Microbiol. 46:333-337.
Crossref

 

García P, Martínez B, Obeso JM, Rodríguez A (2008). Bacteriophages and their application in food safety. Lett. Appl. Microbiol. 47:479-485.
Crossref

 

Garcia P, Madera C, Martinez B, Rodriguez A (2007). Biocontrol of S. aureus in curd manufacturing processes using bacteriophages. Int. Dairy J. 17: 1232-1239.
Crossref

 

Garcia P, Martinez B, Rodriguez L, Rodriguez A (2010). Synergy between the phage endolysin LysH5 and nisin to kill Staphylococcus aureus in pasteurized milk. Int. J. Food. Microbiol. 141:151-155.
Crossref

 

Geier M, Frigg ME, Merril C (1973). Fate of bacteriophage lambda in non-immune germ-free mice. Nature 246:221-222.
Crossref

 

Goodridge L, Abedon ST (2003). Bacteriophage biocontrol and bioprocessing: Application of phage therapy in industry. SIM News 53:254-262.

 

Goodridge L, Chen J, Griffiths M (1999). Development and characterization of a fluorescent-bacteriophage assay for detection of Escherichia coli O157: H7. Appl. Environ. Microbiol. 65:1397-1404.

 

Grandgirard D, Loeffler JM, Fischetti VA, Leib SL (2008). Phage lytic enzyme cpl-1 for antibacterial therapy in experimental Pneumococcal meningitis. J. Infect. Dis.197:1519-1522.
Crossref

 

Guenther S, Huwyler D, Richard S, Loessner MJ (2009). Virulent bacteriophage for efficient biocontrol of Listeria monocytogenes in ready-to-eat foods. Appl. Environ. Microbiol. 75:93-100.
Crossref

 

Gupta A, Onda M, Pastan I, Adhya S, Chaudhary VK (2003). High-density functional display of proteins on bacteriophage λ. J. Mol. Biol. 334:241-254.
Crossref

 

Hagens S, Habel A, von Ahsen U, von Gabain A, Blasi U (2004). Therapy of experimental pseudomonas infections with a non replicating genetically modified phage. Antimicrob. Agents Chemother. 48:3817-3822.
Crossref

 

Hatfull GF, Hendrix RW (2011). Bacteriophages and their genomes. Curr. Opin. Virol. 1:298-303.
Crossref

Hausler T (2006). Viruses vs Superbugs. A Solution to the Antibiotic Crisis? Macmillan.
Crossref

 

Hayes S, Gamage LN, Hayes C (2010). Dual expression system for assembling phage λ display particle vaccine to porcine Circovirus 2 (PCV2). Vaccine 28: 6789-6799.
Crossref

 
 

Hennes KP, Suttle CA (1995). Direct counts of viruses in natural waters and laboratory cultures by epifluorescence microscopy. Limnol. Oceanogr. 40:1050-1055.
Crossref

 
 

Huff WE, Huff GR, Rath NC, Balog JM, Donoghue AM (2003). Evaluation of aerosol spray and intramuscular injection of bacteriophage to treat an Escherichia coli respiratory infection. Poult. Sci. 82:1108-1112.
Crossref

 
 

Hung CH, Kuo CF, Wang CH, Wu CM, Tsao N (2011). Experimental phage therapy in treating Klebsiella pneumoniae-mediated liver abscesses and bacteremia in mice. Antimicrob. Agents Chemother. 55:1358-1365.
Crossref

 
 

Jalasvuori M, Friman VP, Nieminen A, Bamford JK, Buckling A (2011). Bacteriophage selection against a plasmid-encoded sex apparatus leads to the loss of antibiotic-resistance plasmids. Biol. Lett. 7:902-905.
Crossref

 
 

Jamalludeen N, Johnson RP, Shewen PE, Gyles CL (2009). Evaluation of bacteriophages for prevention and treatment of diarrhea due to experimental enterotoxigenic Escherichia coli O149 infection of pigs. Vet. Microbiol. 136:135-141.
Crossref

 
 

Jikia D, Chkhaidze N, Imedashvili E, Mgaloblishvili I, Tsitlanadze G, Katsarava R (2005). The use of a novel biodegradable preparation capable of the sustained release of bacteriophages and ciprofloxacin, in the complex treatment of multidrug-resistant Staphylococcus aureus-infected local radiation injuries exposure to Sr90. Clin. Exp. Dermatol. 30:23-26.
Crossref

 
 

Kaczkowski H, Weber-Dabrowska B, Dabrowski M, Zdrojewicz Z, Cwioro F (1990). Use of bacteriophages in the treatment of chronic bacterial diseases. Wiad. Lek. 43:136-141.

 
 

Katsarava R, Alavidze Z (2004). Polymer blends as biodegradable matrices for preparing biocomposites. U.S. patent 6,703,040. Intralytix, Inc., U.S.A.

 
 

Keary R, McAuliffe O, Ross RP, Hill C, O'Mahony J, Coffey A (2013). Bacteriophages and their endolysins for control of pathogenic bacteria. In: Microbial Pathogens and Strategies for Combating Them: Science, Technology and Education, pp. 1028-1040, (Méndez-Vilas, A. ed). Formatex Research Center, Spain.

 
 

Kishor C, Mishra RR, Saraf SK, Kumar M, Srivastav AK, Nath G (2016). Phage therapy of staphylococcal chronic osteomyelitis in experimental animal model. Ind. J. Med. Res.143:87-94
Crossref

 
 

Kodikara CP, Crew HH, Stewart GS (1991). Near on-line detection of enteric bacteria using lux recombinant bacteriophage. FEMS Microbiol. Lett. 67:261-265.
Crossref

 
 

Krom RJ, Bhargava P, Lobritz MA, Collins JJ (2015). Engineered phagemids for non-lytic, targeted antibacterial therapies. Nano Lett. 15: 4808-4813.
Crossref

 
 

Kutter E, Sulakvelidze A (2005). ntroduction. In: Bacteriophage: Biology and Application, pp. 1–4, (Kutter, E. and Sulakvelidze, A., eds). CRC Press, Florida.

 
 

Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S (2010). Phage therapy in clinical practice: Treatment of human infections. Curr. Pharm. Biotechnol. 11:69-86.
Crossref

 
 

Leszczynski P, Weber-Dabrowska B, Kohutnicka M, Luczak M, Gorski A (2006). Successful eradication of methicillin-resistant Staphylococcus aureus (MRSA) intestinal carrier status in a healthcare worker- case report. Folia Microbiol. 51:236-238.
Crossref

 
 

Li Q, Shivachandra SB, Leppla SH, Rao VB (2006a). Bacteriophage T4 capsid: A unique platform for efficient surface assembly of macromolecular complexes. J. Mol. Biol. 363:577-588.
Crossref

 
 

Li XH, Tang L, Liu D, Sun HM, Zhou CC, Tan LS (2006b). Antitumor effect of recombinant T7 phage vaccine expressing xenogenic vascular endothelial growth factor on Lewis lung cancer in mice. Ai Zheng 25:1221-1226.

 
 

López-Cuevas O, Castro-del Campo N, Chaidez C (2016). Biocontrol of Salmonella typhimurium growth in tomato surface by bacteriophage P22. Afr. J. Microbiol. Res. 10:528-534.
Crossref

 
 

Lu TK, Koeris MS (2011). The next generation of bacteriophage therapy. Curr. Opin. Microbiol.14:524-531.
Crossref

 
 

March JB, Clark JR, Jepson CD (2004). Genetic immunisation against hepatitis B using whole bacteriophage λ particles. Vaccine 22:1666-1671.
Crossref

 
 

Marinelli LJ, Fitz-Gibbon S, Hayes C, Bowman C, Inkeles M, Loncaric A (2012). Propionibacterium acnes bacteriophages display limited genetic diversity and broad killing activity against bacterial skin isolates.MBio3: e00279-12
Crossref

 
 

Markoishvili K, Tsitlanadze G, Katsarava R, Morris JG Jr., Sulakvelidze A (2002). A novel sustained-release matrix based on biodegradable poly(ester amide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds. Int. J. Dermatol. 41:453-458.
Crossref

 
 

Marti E, Variatza E, Balcázar JL (2014). Bacteriophages as a reservoir of extended-spectrum β-lactamase and fluoroquinolone resistance genes in the environment. Clin. Microbiol. Infect. 20: 0456-0459.

 
 

McAuliffe O, Ross RP, Fitzgerald GF (2007). The new phage biology: From genomics to applications. In:Bacteriophage: Genetics and Molecular Biology, pp. 1-42, (Mc Grath, S. and Van Sindren, D., eds). Caister Academic Press.

 
 

Mendes JJ, Leandro C, Corte-Real S, Barbosa R, Cavaco-Silva P, Melo-Cristino J (2013). Wound healing potential of topical bacteriophage therapy on diabetic cutaneous wounds. Wound Repair Regen. 21:595-603.
Crossref

 
 

Merabishvili M, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N (2009). Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS ONE4: e4944.
Crossref

 
 

Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S (1996). Long-circulating bacteriophage as antibacterial agents. Proc. Natl. Acad. Sci. USA 93:3188-3192.
Crossref

 
 

Merril CR, Geier MR, Petricciani JC (1971). Bacterial virusgene expression in human cells. Nature 233:398-400.
Crossref

 
 

Merril CR, Scholl D, Adhya S (2006). Phage therapy. In: The Bacteriophages, 2nd edn., (Calendar, R. ed). Oxford University Press, New York. pp. 725-741.

 
 

Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, Fortuna W, Letkiewicz S, Szufnarowski K (2012). Clinical aspects of phage therapy. Adv. Virus Res. 83:73-121.
Crossref

 
 

Miller RW, Skinner J, Sulakvelidze A, Mathis GF, Hofacre CL (2010). Bacteriophage therapy for control of necrotic enteritis of broiler chickens experimentally infected with Clostridiumperfringens. Avian Dis. 54: 33-40.
Crossref

 
 

Monk AB, Rees CD, Barrow P, Hagens S, Harpe DR (2010). Bacteriophage applications: where are we now? Lett. App. Microbiol. 51:363-369.
Crossref

 
 

Morello E, Saussereau E, Maura D, Huerre M, Touqui L, Debarbieux L (2011). Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS One6:e16963.
Crossref

 
 

Nelson D, Loomis L, Fischetti VA (2001). Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc. Natl. Acad. Sci. USA 98:4107-4112.
Crossref

 
 

Nixon AE, Sexton D, Ladner RC (2014). Drugs derivedfrom phage display. MAbs 6:73-85.
Crossref

 
 

Orndorff PE (2016). Use of bacteriophage to target bacterial surface structuresrequired for virulence: a systematic search for antibiotic alternatives. Curr. Genet. 62:753-757.
Crossref

 
 

Parracho HM, Burrowes BH, Enright MC, McConville ML, Harper DR (2012). The role of regulated clinical trials in the development of bacteriophage therapeutics. J. Mol. Genet. Med. 6:279-286.
Crossref

 
 

Paschke M (2006). Phage display systems and their applications. Appl. Microbiol. Biotechnol. 70:2-11.
Crossref

 
 

Perepanova TS, Darbeeva OS, Kotliarova GA, Kondrat'eva EM, Maiskaia LM, Malysheva VF (1995). The efficacy of bacteriophage preparations in treating inflammatory urologic diseases. Urol. Nefrol. (Mosk) 5:14-17.

 
 

Pouillot F, Chomton M, Blois H, Courroux C, Noelig J, Bidet P (2012). Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b:H4-ST131 Escherichia coli strain producing CTX-M-15. Antimicrob. Agents. Chemother. 56: 3568-3575.
Crossref

 
 

Proskurov VA (1970). Use of staphylococcal bacteriophage for therapeutic and preventive purposes. Zh. Mikrobiol. Epidemiol. Immunobiol. 47: 104-107.

 
 

Ramesh V, Fralick JA, Rolfe RD (1999). Prevention of Clostridium difficile induced ileocecitis with bacteriophage. Anaerobe 5:69-78.
Crossref

 
 

Rath D, Amlinger L, Rath A, Lundgren M (2015). The CRISPR-Cas immune system: Biology, mechanisms and applications. Biochimie. 117:119-128.
Crossref

 
 

Rees C, Loessner M (2005). Phage for the detection of pathogenic bacteria. In: Bacteriophage: Biology and Application, pp. 267-284, (Kutter, E. and Sulakvelidze, A., eds). CRC Press, Florida.

 
 

Rossi LP, Almeida RC, Lopes LS, Figueiredo AC, Ramos MP, Almeidia PF (2011). Occurrence of Listeria spp. in Brazilian fresh sausage and control of Listeria monocytogenes using bacteriophage P100. Food Control 22: 954-958.
Crossref

Sakaguchi Y, Hayashi T, Kurokawa K, Nakayama K, Oshima K, Fujinaga Y (2005). The genome sequence of Clostridium botulinum type C neurotoxin-converting phage and the molecular mechanisms of unstable lysogeny. PNAS102: 17472-17477.

 

Schmelcher M, Powell AM, Becker SC, Camp MJ, Donovan DM (2012). Chimeric phage lysins act synergistically with lysostaphin to kill mastitis-causing Staphylococcus aureus in murine mammary glands. Appl. Environ. Microbiol. 78:2297-2305.
Crossref

 
 

Seed KD (2015). Battling phages: How bacteria defend against viral attack. PLoS Pathogen.11:e1004847.
Crossref

 
 

Segundo N, Hernández E, López O, Torres O (2010). Los bacteriófagos como una alternativa en el tratamiento de enfermedades infecciosas Bacterianas (Fagoterapia). Rev. Mex. Cienc. Farm 41:17-26.

 
 

Sherman M (2008). Bacteriophages: beyond antibiotics. U.S. Pharm.33: 1-12.

 
 

Sidhu, S.S. (2000). Phage display in pharmaceutical biotechnology. Curr. Opin. Biotechnol. 11:610-616.
Crossref

 
 

Slopek S, Weber-Dabrowska B, Dabrowski M, Kucharewicz-Krukowska A (1987). Results of bacteriophage treatment of suppurative bacterial infections in the years 1981–1986. Arch. Immunol. Ther. Exp. (Warsz) 35:569-583.

 
 

Smith GP (1985). Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Sci. 228:1315-1317.
Crossref

 
 

Smith HW, Huggins MB (1982). Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J. Gen. Microbiol. 128:307-318.
Crossref

 
 

Smith HW, Huggins MB (1983). Effectiveness of phages in treating experimental E. coli diarrhoea in calves, piglets and lambs. J. Gen. Microbiol.129: 2659-2675.
Crossref

 
 

Soni KA, Nannapaneni R (2010). Removal of Listeria monocytogenes biofilms with bacteriophage P100. J. Food Prot. 73: 1519-1524.
Crossref

 
 

Spricigo DA, Bardina C, Cortés P, Llagostera M (2013). Use of a bacteriophage cocktail to control Salmonella in food and the food industry. Int. J. Food Microbiol.165:169-174.
Crossref

 
 

Stratmann J, Strommenger B, Stevenson K, Gerlach GF (2002). Development of a peptidemediated capture PCR for detection of Mycobacterium avium subsp paratuberculosis in milk. J. Clin. Microbiol. 40:4244-4250.
Crossref

 
 

Stroj L, Weber-Dabrowska B, Partyka K., Mulczyk M, Wojcik M (1999). Successful treatment with bacteriophage in purulent cerebrospinal meningitis in a newborn. Neurol. Neurochir. Pol. 33:693-698.

 
 

Sulakvelidze A, Kutter E (2005). Bacteriophage therapy in humans. In: Bacteriophage: Biology and Application, pp. 381-436, (Kutter, E. and Sulakvelidze, A., eds). CRC Press, Florida.

 
 

Sulakvelidze A, Alavidze Z, Morris JGJ (2001). Bacteriophage therapy. Antimicrob. Agents Chemother. 45:649-659.
Crossref

 
 

Summers WC (1999). Bacteriophage discovery, Felix d'Herelle and the Origins of Molecular Biology. Yale University Press.

 
 

Summers WC (2005). Bacteriophage research: Early history. In: Bacteriophage: Biology and Application, pp. 5-27, (Kutter, E. and Sulakvelidze, A., eds). CRC Press, Florida.

 
 

Tanji Y, Shimada MT, Yoichi M, Miyanaga K, Hori K, Unno H (2004). Toward rational control of Escherichia coli O157:H7 by a phage cocktail. Appl. Microbiol. Biotechnol. 64:270-274.
Crossref

 
 

Tesfaye W, Melese A, Henok S, Yohannis M (2017). Prevalence and antimicrobial susceptibility profile of Salmonella sp from ready-to-eat foods from catering establishments in Jigjiga City, Ethiopia, Afr. J. Microbiol. Res. 10: 1555-1560.
Crossref

 
 

Tesfaye W, Ketema B, Melese A, Henok S (2015). Prevalence and Antibiotics Resistance Patterns of S. aureus Isolated from Kitchen Sponge's at Jimma Town Food Establishments, South West Ethiopia. Int. J. Res. Stud. Biosci. 3: 63-71.

 
 

Tomat D, Migliore L, Aquili V, Quiberoni A, Balagué C (2013). Phage biocontrol of enteropathogenic and shiga toxin-producing Escherichia coli in meat products. Front. Cell Infect. Microbiol. 3:20-29.
Crossref

 
 

Turnbough CL (2003). Discovery of phage display peptide ligands for species-specific detection of Bacillus spores. J. Microbiol. Method. 53:263-271.
Crossref

 
 

Verheust C, Pauwels K, Mahillon J, Helinski D, Herman P (2010). Contained use of bacteriophages: risk assessment and biosafety recommendations. Appl. Biosaf. 15:32-44.
Crossref

 
 

Viazis S, Akhtar M, Feirtag J, Diez-Gonzalez F (2011). Reduction of Escherichia coli O157:H7 viability on hard surfaces by treatment with a bacteriophage mixture. Int. J. Food Microbiol. 145:37-42.
Crossref

 
 

Vieira A, Silva YJ, Cunha A, Gomes NC, Ackermann HW, Almeida A (2012). Phage therapy to control multidrug-resistant Pseudomonas aeruginosa skin infections: in vitro and ex vivo experiments. Eur. J. Clin. Microbiol. Infect. Dis. 31:3241-3249.
Crossref

 
 

Vieu JF (1975). Les bactériophages. Flammarion, Paris. NOT CITED

 
 

Vinodkumar CS, Kalsurmath S, Neelagund YF (2008). Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonasaeruginosa septicemia in mice. Indian. J. Pathol. Microbiol. 5:360-366.
Crossref

 
 

Vinodkumar CS, Neelagund YF, Kalsurmath S (2005). Bacteriophage in the treatment of experimental septicemic mice from a clinical isolate of multidrug resistant Klebsiella pneumoniae. J. Communicable Dis. 37:18-29.

 
 

Wagenaar JA, van Bergen MA, Mueller MA, Wassenaar TM, Carlton RM (2005) Phage therapy reduces Campylobacter jejuni colonization in broilers. Vet. Microbiol. 109:275-283.
Crossref

 
 

Wall S, Zhang J, Rostagno M, Ebner P (2010). Phage therapy to reduce pre-processing Salmonella infections in market-weight swine. Appl. Environ. Microbiol. 76:48-53.
Crossref

 
 

Wang J, Hu B, Xu M. Yan Q, Liu S, Zhu X (2006a). Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant P. aeruginosa. Int. J. Mol. Med.17:309-317.
Crossref

 
 

Wang J, Hu B, Xu M, Yan Q, Liu S, Zhu X (2006b). Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum β-lactamase-producing Escherichia coli bacteremia. Int. J. Mol. Med.17:347-355.
Crossref

 
 

Watanabe R, Matsumoto T, Sano G, Ishii Y, Tateda K, Sumiyama Y (2007). Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob. Agents Chemother. 51:446-452.
Crossref

 
 

Weber-Dabrowska B, Mulczyk M, Górski A (2001). Bacteriophage therapy for infections in cancer patients. Clin. Appl. Immunol. Rev. 1:131-134.
Crossref

 
 

Wright A, Hawkins C, Anggard E, Harper D (2009). A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 34:349-357.
Crossref

 
 

Yen M, Cairns LS, CamillI A (2017). A cocktail of three virulent bacteriophagesprevents Vibrio cholerae infection in animal models. Nat. Commun. 8:14187.
Crossref

 
 

Yosef I, Manor M, Kiro R, Qimron U (2015). Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. Proc. Natl. Acad. Sci. USA. 112:7267-7272.
Crossref

 
 

Zanghi CN, Sapinoro R, Bradel-Tretheway B, Dewhurst S (2007). A tractable method for simultaneous modifications to the head and tail of bacteriophage λ and its application to enhancing phage-mediated gene delivery. Nucleic Acids Res. 35:e59.
Crossref